Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma


Mitigation of regulatory T cell-mediated immunosuppression and elicitation of immunogenic tumor cell death are crucial events for optimal anti-tumor immune activity in vivo. This study was designed to investigate the potential synergistic activity of the combined use of cyclophosphamide (CP) and doxorubicin (DR), both of which are known to resolve these two… (More)
DOI: 10.1007/s00262-009-0797-1

6 Figures and Tables


  • Presentations referencing similar topics